Literature DB >> 15138626

Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines.

Toshihiro Murata1, Minoru Haisa, Hirokazu Uetsuka, Tetuji Nobuhisa, Takaomi Ookawa, Yoko Tabuchi, Yasuaki Shirakawa, Tomoki Yamatsuji, Junji Matsuoka, Masahiko Nishiyama, Noriaki Tanaka, Yoshio Naomoto.   

Abstract

It is important to clarify the mechanism of resistance to cisplatin for the treatment of solid tumors. We have examined the expression of apoptosis-related proteins, Bax and Bcl-2, in ovarian cancer cells. We used the cell line 2008 and its cisplatin resistant subclone 2008 C-13. The percentage of 2008 cells showing apoptosis was significantly higher following cisplatin treatment as compared to untreated controls. 2008 C-13 cells showing apoptosis did not differ between the cisplatin-treated group and the untreated group. The expression of mRNA and protein of Bax in the two cell lines were not altered by treatment with cisplatin. Although the expression of mRNA and protein of Bcl-2 decreased in 2008 cells after treatment with cisplatin, the expression of Bcl-2 remained unchanged in 2008 C-13 cells. Our results indicate that the down-regulation of Bcl-2 plays an important role in the mechanisms of tumor resistance to anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138626

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  9 in total

Review 1.  Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.

Authors:  Suoyuan Li; Wei Sun; Hongsheng Wang; Dongqing Zuo; Yingqi Hua; Zhengdong Cai
Journal:  Tumour Biol       Date:  2015-02-11

2.  Cisplatin loaded albumin mesospheres for lung cancer treatment.

Authors:  Hung-Yen Lee; Kamal A Mohammed; Eugene P Goldberg; Frederic Kaye; Najmunnisa Nasreen
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

3.  Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistance.

Authors:  Lin-Hai Yan; Wei-Yuan Wei; Wen-Long Cao; Xiao-Shi Zhang; Yu-Bo Xie; Qiang Xiao
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 4.  Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.

Authors:  Yakun Chen; Yong Tang; Changxiong Guo; Jiuhui Wang; Debasish Boral; Daotai Nie
Journal:  Biochem Pharmacol       Date:  2012-02-04       Impact factor: 5.858

5.  Heteroarotinoids with anti-cancer activity against ovarian cancer cells.

Authors:  Thanh C Le; K Darrell Berlin; Stacy D Benson; Margaret A Eastman; Gianna Bell-Eunice; Anna C Nelson; Doris M Benbrook
Journal:  Open Med Chem J       Date:  2007-10-24

6.  Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.

Authors:  Gabriella Ferrandina; Franco O Ranelletti; Enrica Martinelli; Amelia Paglia; Gian Franco Zannoni; Giovanni Scambia
Journal:  BMC Cancer       Date:  2006-07-11       Impact factor: 4.430

7.  Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

Authors:  Chunjing Wu; Medhi Wangpaichitr; Lynn Feun; Marcus Tien Kuo; Carlos Robles; Theodore Lampidis; Niramol Savaraj
Journal:  Mol Cancer       Date:  2005-07-20       Impact factor: 27.401

8.  Molecular mechanisms of chemoresistance in osteosarcoma (Review).

Authors:  Hongtao He; Jiangdong Ni; Jun Huang
Journal:  Oncol Lett       Date:  2014-03-04       Impact factor: 2.967

9.  RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer.

Authors:  Huang Ruihua; Zhang Mengyi; Zhao Chong; Qiu Meng; Ma Xin; Tang Qiulin; Bi Feng; Liu Ming
Journal:  Oncotarget       Date:  2016-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.